Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Robotassisterad prostatabiopsi med en ny ultraljudssond

4 november 2026 uppdaterad av: Johns Hopkins University

Robotassisterad prostata biopsi med en ny ultraljudsprobe

Prostate cancer (PCa) is the most diagnosed type of cancer and the second leading cause of cancer related deaths among US men, and its incidence has increased steadily in the last decade. Efforts to address the rise in PCa diagnosis without overdetection and overtreatment include targeted biopsy techniques for clinically significant PCa using magnetic resonance imaging (MRI), and precision targeted biopsy guided by ultrasound and fused to the MRI.

The study aims to improve prostate biopsy with a novel ultrasound probe and robot developed at Johns Hopkins, the ProBot device. The trial is a Phase 1 clinical trial to evaluate the safety and feasibility of the new device.

ProBot is an entirely new concept including a novel ultrasound probe and robot kinematics specifically designed for the prostate. It operates with only two degrees of freedom configured such that the motions for 3D image scanning and biopsy may not deform the prostate gland, thus improving the accuracy of MRI-ultrasound fusion and needle targeting at biopsy.

ProBot is a small and lightweight robot (1.3Kg including the ultrasound probe). It allows hands-free operation of its ultrasound probe at 3D image scanning and needle targeting supervised by the urologist.

In addition to MRI-targeted biopsy (TB), at systematic biopsy (SB), instead of using the common template plan that is the same for all patients, the innovative software optimizes the plan for each patient to obtain a diagnosis that is representative of the whole gland histology. The ProBot robot is also uniquely capable of transrectal (TR) and transperineal (TP) biopsy.

The aims of the study are to determine the safety and feasibility of the new device at TR and TP biopsies.

Studieöversikt

Status

Rekrytering

Intervention / Behandling

Studietyp

Interventionell

Inskrivning (Beräknad)

60

Fas

  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

  • Namn: Sara A Naizghi
  • Telefonnummer: 720-965-9494 4105501980
  • E-post: snaizgh1@jh.edu

Studieorter

    • Maryland
      • Baltimore, Maryland, Förenta staterna, 21287
        • Rekrytering
        • Johns Hopkins Hospital
        • Kontakt:
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

40 år till 75 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Manlig

Beskrivning

Included in the study will be:

  • Men between the ages of 40 and 75

  • Men must have one of the following "high risk" features:

    1. PSA > 4.0 ng/ml and/or abnormal digital rectal examination (DRE)
    2. ASAP (atypical small acinar proliferation) on previous biopsy
  • Men with mpMRI or bpMRI exams, including both PI-RADS ≤2 and PI-RADS ≥3.

Excluded from the study will be patients without available mpMRI exams and patients:

  • Females and children because of the prostate cancer targeted disease.

  • Patients who are not recommended or in whom TR or TP prostate biopsy is considered high-risk:

    1. Patients with previous rectal surgery.
    2. Patients with anal stenosis or coagulopathy.
    3. Patients on active anticoagulation medication (eg. Coumadin, Lovenox, or Heparin).
    4. Patients who cannot tolerate periprostatic Lidocaine block anesthesia or in whom anesthesia is considered high-risk.
  • Patients who already had a prostate biopsy taken with the ProBot investigational device.

  • Vulnerable populations, such as prisoners, institutionalized individuals.

  • Patients who are unwilling or unable to sign informed consent (no assent required).

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Enhetens genomförbarhet
  • Tilldelning: Icke-randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Transrectal biopsy (TR)

Biopsy guided by transrectal ultrasound fused with MRI and needle inserted on a transrectal path

Precision personalized prostate biopsy with a novel ultrasound probe and robot, ProBot

Experimentell: Transperineal biopsy (TP)

Biopsy guided by transrectal ultrasound fused with MRI and needle inserted on a transperineal path.

Precision personalized prostate biopsy with a novel ultrasound probe and robot, ProBot

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Device feasibility as assessed by patient discomfort score
Tidsram: Immediately after the procedure

Scale 1-10, 10 highest discomfort

Immediately after the procedure
Device feasibility as assessed by maximal procedural pain
Tidsram: Immediately after the procedure

Scale 1-10, 10 highest pain

Immediately after the procedure
Device feasibility as assessed by the rate of complications
Tidsram: Throughout the study, each case recorded within 1 month of the procedure

Rate of complications

Throughout the study, each case recorded within 1 month of the procedure
Device feasibility as assessed by serious adverse events
Tidsram: Up to 1 month post procedure

Serious Adverse events throughout the study

Up to 1 month post procedure
Device feasibility as assessed by the rate of successful completion of cases
Tidsram: Immediately post procedure

Rate of cases completed successfully throughout the study

Immediately post procedure
Device feasibility as assessed by the procedure time
Tidsram: Immediately post procedure

Times of the procedures measured in minutes throughout the study

Immediately post procedure

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Prostate cancer detection rates at targeted biopsy (TB)
Tidsram: Up to 1 month post procedure

Clinically significant PCa detection rates at TB throughout the study

Up to 1 month post procedure
Prostate cancer detection rates at systematic biopsy (SB)
Tidsram: Up to one month post procedure

Clinically significant PCa detection rates at SB throughout the study

Up to one month post procedure
Needle targeting errors
Tidsram: Immediately post procedure

Measured in ultrasound throughout the study

Immediately post procedure
Prostate deformations (mm)
Tidsram: Immediately post procedure

Maximum deformation of the gland between the start and end of the procedure measured in [mm] throughout the study

Immediately post procedure
Prostate displacement (mm)
Tidsram: Immediately post procedure

Displacement of the gland between the start and end of the procedure measured in [mm] throughout the study

Immediately post procedure

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Misop Han, MD, Johns Hopkins University

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

23 september 2025

Primärt slutförande (Beräknad)

31 maj 2030

Avslutad studie (Beräknad)

31 maj 2030

Studieregistreringsdatum

Först inskickad

25 november 2025

Först inskickad som uppfyllde QC-kriterierna

25 november 2025

Första postat (Faktisk)

8 december 2025

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

6 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

4 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Ja

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera